



# Smoking Cessation: What are the Barriers?

Cary A. Presant, MD, FACP, FASCO, FACCC

Professor, Department of Medical Oncology & Therapeutics Research  
Clinical Co- Director, The National Cancer Institute (NCI) MOONSHOT Cancer  
Center Cessation Initiative (C3I)  
City of Hope

# Disclosures

- I do not have any relevant financial relationships.

*This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.*

# Cultural Linguistic Competency (CLC) & Implicit Bias (IB)

## STATE LAW:

The California legislature has passed Assembly Bill (AB) 1195, which states that as of July 1, 2006, all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component. It has also passed AB 241, which states that as of January 1, 2022, all continuing education courses for a physician and surgeon **must** contain curriculum that includes specified instruction in the understanding of implicit bias in medical treatment.

*The cultural and linguistic competency (CLC) and implicit bias (IB) definitions reiterate how patients' diverse backgrounds may impact their access to care.*

## EXEMPTION:

Business and Professions Code 2190.1 exempts activities which are dedicated solely to research or other issues that do not contain a direct patient care component.

## ***The following CLC & IB components will be addressed in this presentation:***

- *Higher frequency of smoking in African Americans.*
- *Higher frequency in smoking in low socioeconomic status patients.*

# WHY IS TOBACCO CESSATION IMPORTANT TO CANCER PROVIDERS?

## WHY IS TOBACCO CESSATION THE 4<sup>TH</sup> PILLAR OF CANCER CARE?

- **SURGERY INCREASED COMPLICATIONS**
  - WOUND HEALING, INFECTION, PULMONARY COMPLICATIONS, ANESTHESIA COMPLICATIONS
  - INCREASED READMISSIONS
- **RADIATION THERAPY**
  - DECREASED EFFICACY
  - INCREASED TOXICITY: MUCOSITIS, PNEUMONITIS, SOFT TISSUE NECROSIS, LOSS OF VOICE
- **CHEMOTHERAPY**
  - DECREASED RESPONSE
  - INCREASED DRUG INTERACTIONS (P450: e.g. IRINOTECAN, BENDAMUSTINE, ERLOTNIB)
  - INCREASED INFECTION, GREATER WEIGHT LOSS, FATIGUE, CARDIOTOXICITY
- **STEM CELL TRANSPLANT**
  - INCREASED COMPLICATIONS
  - REDUCED SURVIVAL
- **PALLIATIVE CARE**
  - POOR PAIN CONTROL, WORSE RESPIRATORY DISTRESS
  - INCREASED OXYGEN NEED, DECREASED QUALITY OF LIFE

## EVIDENCE BASED GUIDELINES

- 23% OF CANCER PATIENTS SMOKE AT TIME OF DIAGNOSIS
- GUIDELINES UNIVERSALLY CALL FOR IMPLEMENTING TOBACCO CESSATION
  - ***NCCN GUIDELINES***
    - *UPDATED 2022 (DR BRIAN TIEP, COH)*
  - ***US PUBLIC HEALTH SERVICE***
    - *UPDATED 1996, 2000, 2008*
  - ***US PREVENTIVE SERVICES TASK FORCE***
    - *UPDATED 2021*

## ***NCCN GUIDELINES OVERVIEW***

- **EVALUATE SMOKING HISTORY AND DOCUMENT\***
- **CESSATION MANAGEMENT: MEDICATIONS \* AND COUNSELING**
- **RELAPSE RISK ASSESSMENT**
- **MONITOR FOR RELAPSE AND DOCUMENT\***
- **ALTERNATIVE APPROACHES CONSIDERED**
  - **E-CIGARETTES/VAPING (NOT STANDARD DUE TO EVALI RISK)**
  - **HYPNOSIS, ACUPUNCTURE**
  - **NUTRITIONAL SUPPLEMENTS, EXERCISE**
- **RESOURCES: FOR PATIENTS AND FOR PROVIDERS \***
- **PHARMACOTHERAPY PRINCIPLES \***
  - **DOSES, ADMINISTRATION, ADVERSE EFFECTS, CONTRAINDICATIONS**
- **DISCUSSION**

## WHAT ARE THE BARRIERS TO TOBACCO CESSATION? *PATIENT BARRIERS AND HURDLES*

- PATIENTS REFUSE TO CONSIDER OR DO NOT RESPOND TO CALL: 82% (J. Burris JCO-OP 2022)
  - YOUNGER, MALE, HEMATOLOGIC MALIGNANCY, MORE DISTRESS
- MEDICATIONS EXPENSIVE
- EASY CIGARETTE ACCESS, HEAVY SMOKING HISTORY OR YOUNGER WHEN SMOKING STARTED
- STRESS, ANXIETY, DEPRESSION, WORK OR FAMILY PROBLEMS (J. Ferra Europ Resp J 2019)
- DESIRE TO MAINTAIN CONTROL ( M Wells BMC Cancer 2017)
- LACK OF UNDERSTANDING OF REDUCED OUTCOMES, BELIEF IT IS NOT IMPORTANT (G Warren J Thor Oncol 2015)
- SHAME AND GUILT OVER CAUSE OF CANCER (M Cedzynska Tob Prev Cessation 2020)
- HEAVY ALCOHOL USE
- LANGUAGE PROBLEM
- CONTRAINDICATION TO USE OF MEDICATIONS (NRT, VARENICLINE)
- RELAPSES

## WHAT ARE THE BARRIERS TO TOBACCO CESSATION? *PHYSICIAN AND APP BARRIERS AND HURDLES*

- BELIEF IT DOES NOT IMPROVE OUTCOMES (6% curative 26% palliative J Derksen Eur J Ca 2020)
- DIDN'T DISCUSS CESSATION (12% curative 46% palliative)
- DIDN'T DISCUSS MEDICATIONS OR PROVIDE CESSATION SUPPORT (69% curative 82% palliative)
- RELUCTANT TO REMOVE A PLEASURE (13% curative 54% palliative)
- LACK OF TIME
- LACK OF RESOURCES OR CESSATION MATERIALS (71%)
- LACK OF EDUCATION (73% said they need more)
- MORE APPROPRIATE FOR PCP (58%)
- NO REIMBURSEMENT (22%)
- LACK OF TOBACCO TREATMENT CENTER FOR FACE TO FACE OR VIDEO COUNSELING (62%)



## WHAT ARE THE BARRIERS TO TOBACCO CESSATION? *INSTITUTIONAL BARRIERS AND HURDLES*

- LACK OF SUSTAINABLE LEADERSHIP SUPPORT FOR TOBACCO CESSATION POLICY AND STAFFING
- INFORMATION TECHNOLOGY HESITANCY TO PROVIDE EASY REFERRAL AIDS FOR CESSATION
  - OPT OUT TECHNOLOGY FOR AUTOMATIC REFERRAL UNLESS CLINICIANS OBJECT
  - BEST PRACTICE ADVISORY OR CLINICIAN PROMPTS
  - TELEHEALTH DIGITAL SOLUTIONS
- EDUCATIONAL RESOURCES FOR CLINICIANS, STAFF AND PATIENTS
- LACK OF TOBACCO USE SCREENING AND ASSESSMENT TOOLS
- ASSISTANCE WITH OVERCOMING FINANCIAL BARRIERS OF MINORITY PATIENTS
- PROVIDING MULTI-LINGUAL AND CULTURALLY SENSITIVE SUPPORT
- PROVIDING RESOURCES TO MEASURE REACH AND EFFECTIVENESS OF THE TOBACCO CONTROL PROGRAM

## WHAT ARE THE BARRIERS TO TOBACCO CESSATION? *COVID-19 BARRIERS AND HURDLES*

- LESS CESSATION SERVICES (G Warren Current Oncology 2022)
- STAFF AND ADMINISTRATION REDEPLOYED
- REDUCED IN-PERSON SERVICES
- DECREASED MEDICATION DELIVERY
- DELAY IN APPROVALS
- LOWER PRIORITY OF CESSATION
- DECREASED INTER-DEPARTMENTAL OR INTER-AGENCY COMMUNICATION
- DISRUPTION OF PATIENT AND CLINICIAN AND STAFF EDUCATIONAL TRAINING

## *WHEN ARE THE TEACHABLE MOMENTS FOR PATIENTS?*

- TIME WHEN DISCUSSING THE DIAGNOSIS (E Gritz Cancer 2006)
- TIME WHEN DESCRIBING THE TREATMENT PLAN
- PRE-OPERATIVE ANESTHESIA VISIT (C Presant AACR 2022)
- COPD PULMONARY CONSULTATION
- LUNG CANCER LOW DOSE CT SCREENING
- TIME OF PULMONARY FUNCTION TESTING OR DISCUSSING RESULTS

**WHAT I NEED TO DO NOW  
TAKE HOME MESSAGES  
MY HOMEWORK!**

- **PREPARE TO INCREASE CESSATION**
  - **DETERMINE WHERE YOU CAN GET CESSATION COUNSELING SERVICES AT YOUR INSTITUTION, HOSPITAL OR HEALTH PLAN AND HOW TO REFER**
  - **ASK YOUR IT DEPARTMENT FOR AN AUTOMATIC OPT-OUT REFERRAL FOR TOBACCO CESSATION IN YOUR EMR AND SMART PHRASE FOR DOCUMENTING CESSATION VISITS: (COH MODEL)**
  - **GET PATIENT RESOURCES: DIGITAL AND/OR HARD COPY FROM COH AND NCCN**
  - **GET MEDICATION GUIDELINES: NCCN**
- **ASK ADVISE AND REFER for cessation counseling services**
- **PRESCRIBE MEDICATION SUPPORT (NRT, VARENICLINE)**
- **REFER PATIENTS AND FAMILY/FRIENDS TO A SMOKING CESSATION SUPPORT GROUP (COH)**
- **CONSIDER USING BILLING CODES 99406 99407 (cessation) OR UPCODE VISIT**
  - **DOCUMENT SMOKING STATUS AND CESSATION REFERRAL; CAN USE SMARTPHRASE (COH)**
  - **USE 99407/99407 8 TIMES PER YEAR**

## CONTACT INFORMATION

- [SMOKINGCESSATION@COH.ORG](mailto:SMOKINGCESSATION@COH.ORG)
- 626-218-9114
  
- CPRESANT@COH.ORG